RxDoctor Payments Data

Thomas Frazier, MD

Gastroenterology · Louisa, KYNPI 1205966256

Payments from drug & device makers

$4,180in general payments, 2019–2025

Across 275 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$659
  • Evoke Pharma, Inc.$186
  • Redhill Biopharma Inc.$144
  • Aimmune Therapeutics, Inc.$135
  • Nestle Healthcare Nutrition Inc.$87
  • plus $436 from 12 others

What the payments were for

  • Food & beverage$4,180100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,180 in reported general payments places this provider in the 50th percentile of 207 gastroenterology providers in Kentucky.

See all gastroenterology providers in Kentucky

Medicare billing

Part B allowed, 2024
$69,376
Medicare patients
318
Services billed
685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$305,898
EntyvioVedolizumab28$246,167
Humira(Cf) PenAdalimumab13$177,107
RemicadeInfliximab13$68,465
LinzessLinaclotide41$22,606
SutabSod Sulf/Pot Chloride/Mag Sulf49$7,781
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates102$6,956
Dexlansoprazole DrDexlansoprazole15$5,490
MovantikNaloxegol Oxalate11$4,907
Mesalamine23$4,850
ClenpiqSod Picosulf/Mag Ox/Citric Ac22$3,624
Colestipol Hcl30$3,039
LoperamideLoperamide Hcl77$2,994
Fentanyl19$2,891
Sucralfate22$2,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Remicade$85$374,36225 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$76$246,16728 claims
AbbVieLinzess$2,534$22,60641 claims
Redhill Biopharma Inc.Movantik$144$4,90711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 207 gastroenterology providers in Kentucky.

Other gastroenterology in Louisa

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →